Dr. Gudjonsson discusses a recently published research letter in which he and his colleagues discuss ongoing subclinical inflammation present in between flares in patients with GPP, and the effect of treatment with spesolimab on this inflammation.
Reference:
- Lebwohl M, Sarkar M, Krueger J, et al. Targeting the IL-36 receptor with spesolimab mitigates residual inflammation and prevents generalized pustular psoriasis flares. J Clin Invest. 2025; 135(13):e195673.